Form 8-K - Current report:
SEC Accession No. 0001493152-24-044006
Filing Date
2024-11-07
Accepted
2024-11-07 16:05:35
Documents
15
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39163
2 ex99-1.htm EX-99.1 75909
3 ex99-1_001.jpg GRAPHIC 18308
  Complete submission text file 0001493152-24-044006.txt   333164

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ltrn-20241107.xsd EX-101.SCH 3030
5 XBRL LABEL FILE ltrn-20241107_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE ltrn-20241107_pre.xml EX-101.PRE 24175
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3793
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

EIN.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39318 | Film No.: 241435520
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)